Sign in

    Iain Simpson

    Vice President and Equity Analyst at Barclays

    Iain Simpson is a Vice President and Equity Analyst at Barclays, specializing in coverage of multinational consumer and healthcare companies such as Henkel, Beiersdorf, and GlaxoSmithKline. He has built a track record covering 17 stocks with a 57.81% success rate, highlighted by a notable 43.2% one-year return on a Church & Dwight recommendation. Simpson began his research analyst career prior to joining Barclays, and has established himself within the general sector, producing consistent stock calls with quantifiable performance metrics. He holds professional securities research credentials and is recognized for his analytical depth and systematic investment approach in European equities.

    Iain Simpson's questions to Haleon (HLN) leadership

    Iain Simpson's questions to Haleon (HLN) leadership • Q2 2024

    Question

    Iain Simpson sought to confirm the magnitude of the phenylephrine destocking impact on group volume and questioned the drivers for increased A&P spending in H2. He later asked about the translation of EBIT to EPS, inquiring about the outlook for finance costs, tax rate, and share count.

    Answer

    CFO Tobias Hestler confirmed the phenylephrine volume impact was a 0.5 point swing for the group. He detailed that lower H2 profit growth is due to lapping lower cost inflation, higher A&P and R&D spend, and other phasing effects. He also confirmed that net finance costs, tax rate, non-controlling interests, and share count are all trending favorably to support future EPS growth.

    Ask Fintool Equity Research AI